CTMX

CytomX Therapeutics, Inc.

1.30 USD
+0.01 (+0.78%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

CytomX Therapeutics, Inc. stock is down -28.96% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
01 May 15:29 21 Jun, 2024 5.00 CALL 4850 0
01 May 18:08 17 May, 2024 7.50 CALL 500 0
01 May 19:02 21 Jun, 2024 5.00 CALL 4998 0
03 May 18:15 17 May, 2024 5.00 CALL 1464 5290
07 May 15:10 17 May, 2024 5.00 CALL 376 7034
07 May 18:15 17 May, 2024 5.00 CALL 362 7034
07 May 18:16 17 May, 2024 5.00 CALL 347 7034
07 May 19:14 17 May, 2024 5.00 CALL 308 7034
08 May 15:38 17 May, 2024 2.50 PUT 1000 3833
08 May 16:51 17 May, 2024 5.00 CALL 362 10541

About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the. treatment of breast cancer, head and neck squamous cell carcinoma, and diffuse large B-cell lymphoma.